To recreate in the laboratory the formation of Lewy bodies as they would occur in a Parkinson’s patient, two ingredients are required: the protein α-synuclein and the participation of the immune system. The results could prevent the development and progression of this neurodegenerative disorder and help in the search for new therapies. Read More
Booster Therapeutics is ready to open up a new arm of the proteasome after raising $15 million in seed funding to advance small molecules it says can degrade multiple types of harmful proteins. Rather than tagging single disease proteins with a ubiquitin marker for degrading via 26S proteasomes, these compounds directly activate 20S proteasomes that naturally recognize disordered proteins without the need for ubiquitin tagging. Read More
Ibio Inc. has announced progress under its collaboration with Astralbio Inc. on a joint myostatin program for cardiometabolic disease and obesity. Ibio leveraged its technology to rapidly advance the program from inception to in vitro proof of concept in human muscle cells. Read More
Facioscapulohumeral muscular dystrophy (FSHD) is a severe muscle disorder caused by aberrant DUX4 mRNA expression in skeletal muscle. DUX4 activates downstream target transcriptome, known as D4T, leading to myofiber loss and muscle weakness. Read More
Aberrant expression of G9a and NSD2 has been identified in multiple types of cancer. Therefore, dual-target inhibitors blocking both pathways may be considered a potential strategy to treat solid tumors. Researchers from Sun Yat-Sen University reported on the discovery and preclinical characterization of W-4032, a dual G9a/NSD2 inhibitor aimed to be used for the treatment of solid tumors. Read More
Keybioscience AG and Eli Lilly & Co. have agreed to extend their collaboration on the development of dual amylin and calcitonin receptor agonists (DACRAs), a new class of potential treatments for obesity and related disorders. Read More
University of Miami has patented new vasopressin V1A receptor antagonists reported to be useful for the treatment of osteoporosis, Paget disease and cancer. Read More
Satellos Bioscience Inc. has developed and presented data for a compound that targeted the process of muscle regeneration based on modulation of satellite stem cell polarity. Read More
Pantetheinase (Vanin-1) inhibitors are described in an Athos Therapeutics Inc. patent as potentially useful for the treatment of autoimmune disease, cancer and inflammatory disorders. Read More
Work at Vivozon Inc. has led to the identification of dual metabotropic glutamate mGlu5 receptor antagonists and histone deacetylase 6 (HDAC6) inhibitors. Read More
EZH2 and LSD1 are histone modification enzymes often overexpressed in several types of aggressive cancer such as colorectal, breast or prostate cancer, among others. Read More
Researchers from Southern Medical University and affiliated organizations presented the discovery and preclinical characterization of novel human urate transporter 1 (hURAT1) inhibitors being developed for the treatment of hyperuricemia. Read More
EA Pharma Co. Ltd. has prepared and tested nitrogen-including heterocycle derivatives acting as 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) inhibitors. Read More
Pancreatic cancer is among the most lethal cancers and the fourth leading cause of cancer deaths worldwide, where 90% of cases fall into the pancreatic ductal adenocarcinoma (PDAC) type. Read More
A TYK Medicines Inc. patent discloses tricyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer. Read More
